Adverse drug reactions and current state of drug regimen review in nursing facilities: Need for a change?

Consultant Pharmacist

Volumn 22, Issue 7, 2007, Pages 586-592

  Bain, Kevin T ^a  

^a excelleRx Inc   (United States)

Author keywords

Adverse drug reactions; Consultant pharmacist; Drug regimen review; Fleetwood model; Interpretive guidelines; Nursing facility; Nursing home; Prospective medication therapy management; State operations manual

Indexed keywords

ARTICLE; DRUG REGIMEN REVIEW; ECONOMIC ASPECT; FLEETWOOD MODEL; HEALTH CARE; HEALTH CARE COST; HEALTH CARE FACILITY; INTERDISCIPLINARY COMMUNICATION; MEDICAL PRACTICE; MEDICATION ERROR; MEDICATION THERAPY MANAGEMENT; METHODOLOGY; NURSING; NURSING HOME; PHARMACIST; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATE OPERATIONS MANUAL; UNITED STATES;

EID: 34447503957     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2007.586     Document Type: Article

References (42)

1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
2. Strand LM, Morley PC, Cipolle RJ et al. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990;24:1093-7.
3. Fouts M, Hanlon J, Pieper C et al. Identification of elderly nursing facility residents at high risk for drug-related problems. Consult Pharm 1997;12:1103-11.
4. Institute of Medicine. Preventing medication errors. Washington, DC: National Academies Press; 2006.
5. Gurwitz JH, Field TS, Avorn J et al. Incidence and preventability of adverse drug events in nursing facilities. Am J Med 2000;109:87-94.
6. Gurwitz JH, Field TS, Judge J et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005;118:251-8.
7. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16.
8. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995;274:29-34.
9. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993;8:289-94.
10. Gandhi TK, Weingart SN, Borus J et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-64.
11. Handler SM, Wright RM, Ruby CM et al. Epidemiology of medication-related adverse events in nursing facilifies. Am J Geriatr Pharmacother 2006;4:264-72.
12. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005;28:851-70.
13. Handler SM, Nace DA, Studenski SA et al. Medication error reporting in long term care. Am J Geriatr Pharmacother 2004;2:190-6.
14. Decker FH. Nursing facilifies, 1977-99: what has changed, what has not? Hyattsville, MD: National Center for Health Statistics; 2005. Available at http://www.cdc.gov/nchs/data/nnhsd/NursingFacilifies1977_99.pdf. Accessed October 15, 2006.
15. Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing facilifies: findings from the 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J Am Geriatr Soc 2005;53:438-43.
16. Bain KT, Weschules DJ, Tillotson P. Prevalence and predictors of medication-related problems. Medicare Patient Management 2006;1:14-27.
17. Field TS, Gurwitz JH, Harrold LR et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004;52:1349-54.
18. Evans RS, Lloyd JF, Stoddard GJ et al. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother 2005;39:1161-8.
19. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996;44:194-7.
20. Field TS, Gurwitz JH, Avorn J et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001;161:1629-34.
21. Nguyen JK, Fouts MM, Kotabe SE et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006;4:36-41.
22. Alfred L, Golden A, Preston RA et al. Implementation of a pharmacist directed program to monitor adverse drug reactions. Consult Pharm 2000;15:1032-7.
23. Zanni GR, Wick JY. Long-term care: changing demographics, changing residents. Consult Pharm 2006;21:14-28.
24. Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997;157:2089-96.
25. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995;155:1949-56.
26. Johnson JA, Bootman JL. Drug-related morbidity and mortality: economic impact of pharmaceutical care. Am J Health Syst Pharm 1997;54:554-8.
27. U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services. Guidance to surveyors for long term care facilities. CMS Manual System. Pub. 100-07 State Operations Provider Certification. Available at http://www.ascp.com/resources/nhsurvey/upload/CMSTransmittal19.pdf. Accessed September 23, 2006.
28. Laucka PV, Hoffman NB. Decreasing medication use in a nursing-home patient-care unit. Am J Hosp Pharm 1992;49:96-9.
29. Cooper JW. Effect of initiation, termination, and reinitiation of consultant clinical pharmacist services in a geriatric long-term care facility. Med Care 1985;23:84-8.
30. Strandberg LR, Dawson GW, Mathieson D et al. Effect of comprehensive pharmaceutical services on drug use in long-term care facilities. Am J Hosp Pharm 1980;37:92-4.
31. Young LY, Leach DB, Anderson DA et al. Decreased medication costs in a skilled nursing facility by clinical pharmacy services. Contemp Pharm Pract 1981;4:233-7.
32. Roberts MS, Stokes JA, King MA et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing facilifies. Br J Clin Pharmacol 2001;51:257-65.
33. Cooper JW. Cost-benefit analysis of consultant pharmacist drug therapy recommendations from monthly drug regimen reviews in a geriatric nursing facility: a one-year study. J Pharmacoepidemiol 1997;6:23-36.
34. Christensen D, Trygstad T, Sullivan R et al. A pharmacy management intervention for optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother 2004;2:248-56.
35. Hennessy S, Bilker WB, Zhou L et al. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA 2003;290:1494-9.
36. Harjivan C, Lyles A. Improved medication use in long-term care: building on the consultant pharmacist's drug regimen review. Am J Manag Care 2002;8:318-26.
37. Briesacher B, Limcangco R, Simoni-Wastila L et al. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing facilifies: a natural experiment. J Am Geriatr Soc 2005;53:991-6.
38. Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J 1999;92:485-90.
39. Feinberg JL. Testing a new pharmacy services model. Available at http://www.hmpcommunications.com/ECPN/displayArticle.cfm?articleID=article4585. Accessed May 12, 2006.
40. Daschner M, Brownstein S, Cameron KA et al. Fleetwood Phase II tests a new model of long-term care pharmacy. Consult Pharm 2000;15:989-1005.
41. Lapane KL, Hughes CM. Adherence to the components of the Fleetwood model: self-reported process measures in the Fleetwood Phase III study. Consult Pharm 2006;21:981-7.
42. Martin CM, McSpadden CS. Changes in the State Operations Manual: implications for consultant pharmacy practice. Consult Pharm 2006;21:948-61.